Multivalent Carriers and Related Vaccine Compositions
Patent Information
- Application Number
- JP2023518836
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-11
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-14
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Claims
1. A vaccine composition comprising a multivalent carrier associated with a plurality of coronavirus antigens, the plurality of coronavirus antigens comprising a first coronavirus antigen from a first coronavirus and a second coronavirus antigen from a second coronavirus different from the first coronavirus.
2. 2. The vaccine composition of claim 1, wherein the multiple coronavirus antigens are displayed on the surface of the multivalent carrier or are partially embedded in the multivalent carrier.
3. 3. The vaccine composition of any one of claims 1-2, wherein the multiple coronavirus antigens include a coronavirus spike protein (S protein) or a portion thereof, a coronavirus nucleocapsid protein (N protein) or a portion thereof, a coronavirus hemagglutinin-esterase protein (HE protein) or a portion thereof, a coronavirus papain-like protease or a portion thereof, a coronavirus 3CL protease or a portion thereof, a coronavirus membrane protein (M protein) or a portion thereof, or a combination thereof.
4. The vaccine composition of any one of claims 1-3, wherein the multiple coronavirus antigens include coronavirus proteins of the same protein type.
5. The vaccine composition of any one of claims 1-3, wherein the multiple coronavirus antigens include coronavirus proteins of different protein types.
6. 6. The vaccine composition of any one of claims 1-5, wherein the first coronavirus antigen, the second coronavirus antigen, or both, comprise a coronavirus S protein or a portion thereof, or a coronavirus S protein RBD or a portion thereof.
7. The coronavirus antigens have about, at least, or at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to each other; Each of the plurality of coronavirus antigens comprises a coronavirus S protein RBD or a portion thereof, and the coronavirus S protein RBDs or portions thereof have about, at least about, or at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to each other: Each of the multiple coronavirus antigens includes: (1) an amino acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and 15-26; or (2) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and 15-26. The first coronavirus antigen includes: (1) an amino acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and 15-26; or (2) an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-12 and 15-26; and / or The vaccine composition of any one of claims 1-6, wherein the second coronavirus antigen comprises: (1) an amino acid sequence having at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:1-12 and 15-26; or (2) an amino acid sequence selected from the group consisting of SEQ ID NOs:1-12 and 15-26.
8. The vaccine composition of any one of claims 1-7, wherein the number of first coronavirus antigen molecules and the number of second coronavirus antigen molecules are in a ratio of from 1:100 to 100:
1.
9. The multiple coronavirus antigens further include one or more of a third coronavirus antigen of the third coronavirus, a fourth coronavirus antigen of the fourth coronavirus, a fifth coronavirus antigen of the fifth coronavirus, a sixth coronavirus antigen of the sixth coronavirus, a seventh coronavirus antigen of the seventh coronavirus, and an eighth coronavirus antigen of the eighth coronavirus, and wherein the first, second, third, fourth, fifth, sixth, seventh and eighth coronaviruses are distinct from one another. The plurality of coronavirus antigens includes three, four, five, six, seven, or eight coronavirus S protein RBDs, where each of the plurality of coronavirus S protein RBDs is different from each other. one or more of the plurality of coronavirus antigens belongs to a coronavirus in the genus Alphacoronavirus and / or Betacoronavirus, and optionally each of the plurality of coronavirus antigens belongs to a coronavirus in the genus Betacoronavirus. Several coronavirus antigens belong to the coronaviruses in the subgenus Sarbecovirus. The first coronavirus and the second coronavirus are in the genus Betacoronavirus, optionally in the subgenus Sarbecovirus; The coronavirus antigens belong to a coronavirus selected from the group consisting of: SARS, SARS-2, WIV1, SHC014, Rf1, RmYN02, pang17, RaTG13, and Rs4081; and / or 9. The vaccine composition of any one of claims 1-8, wherein the first coronavirus, the second coronavirus, or both are selected from the group consisting of: SARS, SARS-2, WIV1, SHC014, Rf1, RmYN02, pang17, RaTG13, and Rs4081.
10. The vaccine composition of any one of claims 1-9, wherein the multiple coronavirus antigens are covalently attached to the multivalent carrier, and optionally the multiple coronavirus antigens are conjugated to the multivalent carrier, or the multiple coronavirus antigens are attached to the multivalent carrier through click chemistry, or the multiple coronavirus antigens are non-covalently attached to the multivalent carrier.
11. The multivalent carrier is selected from the group consisting of: nanoparticles, nanotubes, nanowires, dendrimers, liposomes, ethosomes and aquasomes, polymersomes and niosomes, foams, hydrogels, cubosomes, quantum dots, exosomes, macrophages, and combinations thereof; Multivalent carriers include nanoparticles selected from the group consisting of: lipid-based nanoparticles, polymeric nanoparticles, inorganic nanoparticles, surfactant-based emulsions, nanowires, silica nanoparticles, virus-like particles, peptide or protein-based particles, lipid polymer particles, nanolipoprotein particles, and combinations thereof. The multivalent carrier comprises a virus-like particle (VLP), and optionally the virus-like particle is an Ap205 VLP; and / or 11. The vaccine composition of any one of claims 1-10, wherein the multivalent carrier comprises a self-assembling nanoparticle; and optionally, the self-assembling nanoparticle is an i301 nanoparticle or a variant thereof, or an a mi3 nanoparticle or a variant thereof.
12. a plurality of particle-forming proteins are included, and optionally one or more of the plurality of particle-forming proteins includes a 2-dehydro-3-deoxy-phosphogluconate (KDPG) aldolase or a variant thereof; Optionally, a coronavirus antigen of the plurality of coronavirus antigens is attached to a particle-forming protein of the plurality of particle-forming proteins, and optionally, a coronavirus antigen of the plurality of coronavirus antigens is attached to a particle-forming protein of the plurality of particle-forming proteins through a spy tag / spy catcher binding pair. More optionally, a coronavirus antigen of the plurality of coronavirus antigens comprises a spy tag at a C-terminus of the coronavirus antigen, and a particle-forming protein of the plurality of particle-forming proteins comprises a spy catcher at an N-terminus of the particle-forming protein. More optionally, the coronavirus antigen of the plurality of coronavirus antigens comprises a coronavirus S protein RBD, and the coronavirus S protein RBD comprises a spy tag at the C-terminus of the coronavirus S protein RBD, and the particle-forming protein of the plurality of particle-forming proteins comprises a spy catcher at the N-terminus of the particle-forming protein.
13. 13. The vaccine composition of any one of claims 1-12, further comprising an adjuvant, optionally selected from the group consisting of aluminum hydroxide, alhydrogel, AddaVax, MF59, AS03, Freund's adjuvant, Montanide ISA51, CpG, poly I:C, glucopyranosyl lipid A, flagellin, resiquimod, and combinations thereof.
14. A vaccine composition for use in stimulating an immune response comprising a pharma- ceutically effective amount of the vaccine composition of any one of claims 1-13.
15. A vaccine composition comprising a pharma- ceutically effective amount of the vaccine composition of any one of claims 1-13 for use in treating or preventing a coronavirus infection.
16. A vaccine composition comprising a pharma- ceutically effective amount of the vaccine composition of any one of claims 1-13 for use in treating or preventing a disease or disorder caused by a coronavirus infection.
17. A vaccine composition for use according to any one of claims 14-16, wherein the use induces a neutralizing response against a coronavirus different from the first coronavirus and the second coronavirus, induces a neutralizing response against an additional coronavirus different from the coronavirus to which the multiple coronavirus antigens belong, and / or induces a neutralizing response against a coronavirus to which the multiple coronavirus antigens belong.
18. A kit comprising the vaccine composition of any one of claims 1-13.
